Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2021-08-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202114781 |
| _version_ | 1797285145655377920 |
|---|---|
| author | Giovanna Lalli Jonathan M Schott John Hardy Bart De Strooper |
| author_facet | Giovanna Lalli Jonathan M Schott John Hardy Bart De Strooper |
| author_sort | Giovanna Lalli |
| collection | DOAJ |
| description | On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain. |
| first_indexed | 2024-03-07T17:58:56Z |
| format | Article |
| id | doaj.art-b58865ed2caa4598874cf2c4fbbe5fbf |
| institution | Directory Open Access Journal |
| issn | 1757-4676 1757-4684 |
| language | English |
| last_indexed | 2024-03-07T17:58:56Z |
| publishDate | 2021-08-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj.art-b58865ed2caa4598874cf2c4fbbe5fbf2024-03-02T11:20:35ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842021-08-01138n/an/a10.15252/emmm.202114781Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?Giovanna Lalli0Jonathan M Schott1John Hardy2Bart De Strooper3UK Dementia Research Institute at UCL London UKDementia Research Centre UCL Queen Square Institute of Neurology London UKUK Dementia Research Institute at UCL London UKUK Dementia Research Institute at UCL London UKOn 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.https://doi.org/10.15252/emmm.202114781 |
| spellingShingle | Giovanna Lalli Jonathan M Schott John Hardy Bart De Strooper Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? EMBO Molecular Medicine |
| title | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_full | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_fullStr | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_full_unstemmed | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_short | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_sort | aducanumab a new phase in therapeutic development for alzheimer s disease |
| url | https://doi.org/10.15252/emmm.202114781 |
| work_keys_str_mv | AT giovannalalli aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease AT jonathanmschott aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease AT johnhardy aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease AT bartdestrooper aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease |